Author of

• 16879

  +

  P1.07 - Poster Session with Presenters Present (ID 459)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16932

    +

    P1.07-053 - Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study (ID 6417)

    14:30 - 14:30  |  Author(s): X. Jin
    • Abstract

    Background:
    It has no standard treatment strategy for patients with extensive stage small cell lung cancer （SCLC） who experienced progression with three or more lines of chemotherapy. Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2), has been shown confirming antitumor activity and manageable toxicities in breast and gastric cancers. Until now, couples of clinical trials investigating the efficacy of apatinib on non-small cell lung cancer are ongoing. However, the effects of apatinib on small cell lung cancer are still unclear. We retrospectively assessed the efficacy and safety of apatinib in patients with extensive-stage small cell lung cancers after the failure of second or third-line chemotherapy.
    
    Methods:
    The study group comprised 13 patients who received oral apatinib, at a dose of 500 mg daily, for progression after the failure of second or third-line chemotherapy for extensive-stage small cell lung cancer. Treatment was continued until disease progression. For the patients who had grade 3 or 4 toxicities, the dose of apatinib was decreased to 250mg daily. The patients stopped the treatment if they still had the unacceptable toxicity after dose downregulation. We analyzed safety and response (RECIST 1.1) for the available patients monthly.
    
    Results:
    Between Aug 30, 2015 and May 1, 2016, 13 patients were enrolled. In 13 patients, there were 11 patients available for efficacy and safety evaluation. 5/11 (45.5%) patients experienced dose reduction during treatment. Followed up to July 20, 2016, the median during time of afatinib treatment was 2.8 months (95% confidence interval (CI), 1.67-5.04). According to RECIST criteria, the disease control rate was 81.8%, 9/11 (partial response 18.2%, 2/11 and stable disease 63.6%, 7/11). The most frequent treatment-related adverse events were secondary hypertension (45.5%, 5/11), oral mucositis (27.3%, 3/11), hand-foot syndrome (27.3%, 3/11) and fatigue (27.3%, 3/11). Main grade 3 or 4 toxicities were hypertension (27.3%, 3/11), oral mucositis (9.1%, 1/11) and fatigue (9.1%, 1/11).
    
    Conclusion:
    Apatinib exhibits modest activity and acceptable toxicity for the heavily pretreated patients with extensive-stage small cell lung cancer.